Robust Predictive Performance of MLPAS and CCMLP for Clinical Outcome and Risk Stratification in Patients with Colorectal Cancer
MLPAS is an optimal, independent, and robust prognostic biomarker in the stage II-III CRC population, especially with negative CEA or CA19-9. The CCMLP could effectively classify high recurrence-risk patients who require more focus, monitoring, and treatment for the clinic.
Authors
- Hou‐Qun Ying (ORCID: https://orcid.org/0000-0003-3858-4761)
- Hong-Xin Peng
- Qiu-Ying Ye
- Zhi-Jie Wang (ORCID: https://orcid.org/0000-0003-2930-4668)
- Yuanyuan Wang (ORCID: https://orcid.org/0000-0001-7700-7284)
- Min Lu (ORCID: https://orcid.org/0000-0003-4954-153X)
- Xin Wang (ORCID: https://orcid.org/0000-0002-7296-9406)
- Xue‐Xin Cheng (ORCID: https://orcid.org/0000-0003-2241-2535)
Institutions
- Shangrao Normal University (CN)
- Nanchang University (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
- Affiliated Hospital of Taishan Medical University (CN)
- Second Affiliated Hospital of Nanchang University (CN)
- Shandong First Medical University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Inflammation Research
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/jir.s498028
- Primary Topic
- Colorectal Cancer Screening and Detection
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Nanchang University